Goldman Sachs Group Inc Aurinia Pharmaceuticals Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 2,408,021 shares of AUPH stock, worth $23 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,408,021
Previous 2,254,657 6.8%
Holding current value
$23 Million
Previous $12.9 Million 37.1%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$5.32 - $7.33 $815,896 - $1.12 Million
153,364 Added 6.8%
2,408,021 $17.7 Million
Q2 2024

Aug 13, 2024
BUY
$4.81 - $5.78 $493,039 - $592,467
102,503 Added 4.76%
2,254,657 $12.9 Million
Q1 2024

May 15, 2024
BUY
$4.93 - $9.31 $511,231 - $965,428
103,698 Added 5.06%
2,152,154 $10.8 Million
Q4 2023

Feb 13, 2024
BUY
$7.13 - $9.49 $4.11 Million - $5.47 Million
576,120 Added 39.13%
2,048,456 $18.4 Million
Q3 2023

May 14, 2024
SELL
$7.77 - $12.27 $4.48 Million - $7.07 Million
-576,120 Reduced 28.12%
1,472,336 $11.4 Million
Q3 2023

Nov 14, 2023
SELL
$7.77 - $12.27 $2.11 Million - $3.34 Million
-271,869 Reduced 15.59%
1,472,336 $11.4 Million
Q2 2023

May 14, 2024
BUY
$8.96 - $11.69 $6.76 Million - $8.82 Million
754,631 Added 76.26%
1,744,205 $16.9 Million
Q2 2023

Aug 14, 2023
BUY
$8.96 - $11.69 $6.76 Million - $8.82 Million
754,631 Added 76.26%
1,744,205 $16.9 Million
Q1 2023

May 14, 2024
BUY
$5.94 - $11.27 $3.08 Million - $5.85 Million
518,861 Added 110.23%
989,574 $10.8 Million
Q1 2023

May 11, 2023
BUY
$5.94 - $11.27 $3.08 Million - $5.85 Million
518,861 Added 110.23%
989,574 $10.8 Million
Q4 2022

May 14, 2024
SELL
$4.11 - $8.14 $14,495 - $28,709
-3,527 Reduced 0.74%
470,713 $2.03 Million
Q4 2022

Feb 13, 2023
SELL
$4.11 - $8.14 $14,495 - $28,709
-3,527 Reduced 0.74%
470,713 $2.03 Million
Q3 2022

May 14, 2024
SELL
$6.66 - $12.39 $1.64 Million - $3.05 Million
-246,194 Reduced 34.17%
474,240 $3.57 Million
Q3 2022

Nov 10, 2022
SELL
$6.66 - $12.39 $1.64 Million - $3.05 Million
-246,194 Reduced 34.17%
474,240 $3.57 Million
Q2 2022

May 14, 2024
SELL
$8.95 - $12.8 $11.9 Million - $17 Million
-1,328,022 Reduced 64.83%
720,434 $7.24 Million
Q2 2022

Aug 15, 2022
BUY
$8.95 - $12.8 $3.68 Million - $5.26 Million
410,727 Added 132.62%
720,434 $7.24 Million
Q1 2022

May 16, 2022
BUY
$10.05 - $22.48 $364,664 - $815,686
36,285 Added 13.27%
309,707 $3.83 Million
Q4 2021

Feb 14, 2022
BUY
$17.78 - $33.08 $1.73 Million - $3.22 Million
97,377 Added 55.31%
273,422 $6.25 Million
Q3 2021

Nov 10, 2021
BUY
$10.93 - $23.55 $1.92 Million - $4.15 Million
176,045 New
176,045 $3.9 Million

Others Institutions Holding AUPH

# of Institutions
208
Shares Held
58.6M
Call Options Held
1.14M
Put Options Held
1.51M
View Full List

About Aurinia Pharmaceuticals Inc.

AUPH Quotes by TradingView
  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $1.36B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email